Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary
fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have …

Cancer-associated fibroblasts (CAFs) are a common cell in the tumour microenvironment
with diverse tumour-promoting functions. Their presence in tumours is commonly associated …

Background and objective The real‐world tolerability of pirfenidone and nintedanib in non‐
clinical trial patients is unknown. Many patients with pulmonary fibrosis have significant …

Idiopathic pulmonary fibrosis (IPF) is an advancing and fatal lung disease with increasing
incidence and prevalence. Nintedanib and pirfenidone were approved by the FDA for the …

Abstract Background: RECAP (NCT00662038) was an open-label extension study in
patients with idiopathic pulmonary fibrosis (IPF) who completed either the Assessment of …

Cryptotanshinone (CTS), a lipophilic compound extracted from root of Salvia miltiorrhiza
(Danshen), has demonstrated multiple pharmacological activities, including anti …

Introduction Pirfenidone, an antifibrotic drug, slows-down the disease progression in
idiopathic pulmonary fibrosis (IPF) over 12 months, however limited data on the decline of …

Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal condition that causes severe
scarring of the lungs. While the pathogenesis of IPF continues to be extensively studied and …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disorder
showcasing an interaction between genetic predisposition and environmental risks. This …

Pulmonary fibrosis is a scarring disease of lung tissue, which seriously threatens human
health. Treatment options are currently limited, and effective strategies are still lacking. In the …